- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00110643
Infrared Non-Cutting Laser Therapy for Acne
April 30, 2015 updated by: Jeffrey S. Orringer, University of Michigan
CoolTouch Non-ablative Laser Therapy for Acne Vulgaris
The purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of the skin.
In this study, we are interested in learning how well such a laser works to improve the symptoms of acne.
The laser used in this particular study will be the CoolTouch II® laser, manufactured by ICN Photonics, Inc., and has not been FDA-approved for the treatment of acne.
Study Overview
Detailed Description
The purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of skin.
This type of laser treatment creates changes in a layer of the skin called the dermis without causing an open wound in the skin.
It is not yet clear how much improvement can be seen with these treatments or exactly how the skin's response causes these improvements.
In this study, we are interested in learning how well such a laser works to improve the symptoms of acne.
The laser used in this particular study will be the CoolTouch II® laser, manufactured by ICN Photonics, Inc., and has not been FDA-approved for the treatment of acne.
Study Type
Interventional
Enrollment
50
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0314
- University of Michigan Dermatology Department
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 13 years or older of either gender and of any racial/ethnic group.
- Subjects must have clinically evident acne vulgaris of the facial skin.
- Subjects must understand and sign the informed consent prior to participation.
- Subjects must be in generally good health.
- Subjects must be able and willing to comply with the requirements of the protocol.
- You must live within a reasonable driving distance of Ann Arbor, Michigan, and/or be able to attend all of the scheduled appointments during the study.
Exclusion Criteria:
- Oral retinoid (Accutane) use within 1 year of entry into the study.
- Systemic acne therapies (oral antibiotics) within 4 weeks of entry into the study.
- Topical acne therapies (retinoids, antibiotics) within 2 weeks of entry into the study.
- Microdermabrasion or superficial chemical peels at the sites to be treated within 3 months of entry into the study.
- Subjects with a history of dermabrasion or laser resurfacing at the sites to be treated.
- Use of topical lipid absorbing substances (Clinac AC) within 2 weeks of entry into the study.
- Non-compliant subjects.
- Subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation.
- Subjects using alcohol-based topical solutions or "exfolliating" agents within 2 weeks of entry into the study.
- Subjects with a history of very frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.
- History of keloid scar formation for subjects undergoing biopsies.
- Pregnant or nursing females.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Number of subtypes of acne lesions including papules, pustules, cysts, open comedones, and closed comedones
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
total area of sebum droplets measured using image analysis software
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Study Completion
December 1, 2005
Study Registration Dates
First Submitted
May 11, 2005
First Submitted That Met QC Criteria
May 11, 2005
First Posted (Estimate)
May 12, 2005
Study Record Updates
Last Update Posted (Estimate)
May 4, 2015
Last Update Submitted That Met QC Criteria
April 30, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Derm 494
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Ghurki Trust and Teaching HospitalCompletedAcne Vulgaris | Acne Vulgaris on the FacePakistan
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.Active, not recruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.RecruitingInflammatory Acne VulgarisUnited States
Clinical Trials on CoolTouch II laser
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento... and other collaboratorsCompleted
-
Emad Eldin MohamedCompletedTemporomandibular Joint Dysfunction | Low Level Laser Therapy
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedLaser Therapy, Low-Level
-
Suez Canal UniversityNot yet recruitingPulpitis | Dental Pulp NecrosisEgypt
-
Second Affiliated Hospital of Soochow UniversityRecruitingType 2 Diabetes Mellitus | Chronic Kidney Disease | Renal FunctionChina
-
Manchester University NHS Foundation TrustTopcon Corporation; Optos, PLCWithdrawnDiabetic Macular OedemaUnited Kingdom
-
Johns Hopkins UniversityTerminatedGranular Dystrophy, CornealUnited States
-
University of Sao Paulo General HospitalCompletedOsteoarthritisBrazil
-
Universidade Norte do ParanáUniversidade Estadual de LondrinaCompletedPerformance | Aged | Muscle Strength | Resistance Training | LasersBrazil
-
University of GaziantepCompletedSoft Tissue HealingTurkey (Türkiye)